This inventor holds 31 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Cancer Therapeutics. Top assignees: The Brigham and Women's Hospital, Inc., Dana-Farber-Cancer Institute Inc., Harvard College. Active years: 1991-2026.
Location History:
- Brookline, MA (US) (1997 - 1998)
- Ashland, MA (US) (1991 - 2001)
- Sherborn, MA (US) (1993 - 2002)
- Coral Springs, FL (US) (2013)
- Newton, MA (US) (2001 - 2022)
Company Filing History:
23 out of 1,424 
8 out of 1,265 
6 out of 3,071 
Years Active: 1991-2026
Areas of Expertise:
Title: Michael B Brenner: Pioneering Innovations in Autoantibody-associated Conditions and Metabolic Disorders
Introduction:
In the realm of biomedical research and innovation, Michael B Brenner has contributed immensely to the development of novel methods and compositions to address autoantibody-associated conditions and metabolic disorders. With an impressive number of patents to his name, Brenner has made significant strides in the field of therapeutics by tackling these challenging medical conditions head-on. This article delves into his latest patents, career highlights, notable collaborations, and his overall contribution to the realm of innovations and patents.
Latest Patents:
Michael B Brenner's latest patents highlight his dedication to advancing treatments for autoantibody-associated conditions and metabolic disorders. One of his patents is related to the detection and reduction of T peripheral helper cells (Tph) in autoantibody-associated conditions, with a focus on autoantibody-associated autoimmune diseases. This invention offers methods and compositions for detecting and modulating Tph cells, providing potential therapeutic benefits to individuals at risk or already affected by such conditions.
Additionally, Brenner holds patents for the use of cadherin-11 antagonists in the treatment of obesity-associated conditions and enhancing insulin sensitivity. This discovery offers promising prospects for addressing metabolic disorders through novel pharmaceutical compositions that target cadherin-11.
Career Highlights:
Michael B Brenner's extensive career spans notable institutions in the medical and research fields, including The Brigham and Women's Hospital, Inc., and the Dana-Farber Cancer Institute, Inc. These esteemed organizations have provided him with a platform to conduct groundbreaking research and translate his findings into tangible advancements.
Collaborations:
Brenner has collaborated with several distinguished researchers throughout his career. One notable collaborator is Jack L. Strominger, whose renowned work on the immune system complements Brenner's expertise in autoimmune diseases. Their partnership has likely led to synergistic breakthroughs in unraveling the complexities of autoantibody-associated conditions.
Another significant collaborator is Stephen H. Ip, whose specialization in metabolic disorders aligns seamlessly with Brenner's research focus. Together, they have potentially enhanced the development of therapeutic approaches to combat obesity-associated conditions and improve insulin sensitivity.
Conclusion:
Michael B Brenner's contributions to the realm of innovations and patents in medical science and therapeutics have been remarkable. His patent portfolio, addressing autoantibody-associated conditions and metabolic disorders, reflects his commitment to improving the lives of individuals affected by these challenging medical conditions. Brenner's collaboration with esteemed researchers further underscores the significance of interdisciplinary approaches in advancing medical breakthroughs. As Brenner continues his research and patent endeavors, the world eagerly anticipates his future contributions to the field.